Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.03USD
17 Jan 2018
Change (% chg)

$-0.04 (-0.06%)
Prev Close
$62.07
Open
$62.30
Day's High
$62.59
Day's Low
$61.90
Volume
5,346,634
Avg. Vol
3,647,843
52-wk High
$66.80
52-wk Low
$53.63

Select another date:

Tue, Jan 16 2018

Positive Keytruda lung cancer data sends Merck shares up 6 percent

Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent.

UPDATE 3-Positive Keytruda lung cancer data sends Merck shares up 6 pct

* Results cement Merck's lead in first-line lung cancer market

BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints

* MERCK'S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189)

Merck's Keytruda succeeds in key lung cancer trial

Jan 16 Merck & Co Inc said on Tuesday that a key late-stage study testing its blockbuster drug Keytruda as a treatment for a type of lung cancer was successful.

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda

* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

BRIEF-Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054)

BRIEF-FDA Accepts New Drug Applications For Merck's Doravirine

* FDA ACCEPTS NEW DRUG APPLICATIONS FOR MERCK’S DORAVIRINE, THE COMPANY’S INVESTIGATIONAL NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI), FOR TREATMENT OF HIV-1 INFECTION

BRIEF-Merck’s Keytruda Approved In Japan For Use In The Treatment Of Patients With Urothelial Carcinoma

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) APPROVED IN JAPAN FOR USE IN THE TREATMENT OF PATIENTS WITH UROTHELIAL CARCINOMA THAT IS UNRESECTABLE WITH RADICAL SURGERY WHO HAVE PROGRESSED FOLLOWING CANCER CHEMOTHERAPY

BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

* FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES

U.S. FDA approves new diabetes drug from Merck and Pfizer

A new drug developed by Merck & Co and Pfizer Inc won U.S. approval on Wednesday to treat type II diabetes, the Food and Drug Administration said, adding another competitor to a growing class of treatments.

Select another date: